View in EDS HTML Full Text PDF Full Text

Impact of time‐of‐day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study.

Saved in:
Bibliographic Details
Title: Impact of time‐of‐day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study.
Authors: Naganuma, Atsushi1 (AUTHOR), Kakizaki, Satoru2,3 (AUTHOR) kakizaki@gunma-u.ac.jp, Hatanaka, Takeshi4 (AUTHOR), Hiraoka, Atsushi5 (AUTHOR), Tada, Toshifumi6 (AUTHOR), Hirooka, Masashi7 (AUTHOR), Kariyama, Kazuya8 (AUTHOR), Tani, Joji9 (AUTHOR), Atsukawa, Masanori10 (AUTHOR), Takaguchi, Koichi11 (AUTHOR), Itobayashi, Ei12 (AUTHOR), Fukunishi, Shinya13 (AUTHOR), Tsuji, Kunihiko14 (AUTHOR), Ishikawa, Toru15 (AUTHOR), Tajiri, Kazuto16 (AUTHOR), Toyoda, Hidenori17 (AUTHOR), Koshiyama, Yuichi17 (AUTHOR), Ogawa, Chikara18 (AUTHOR), Nishikawa, Hiroki19 (AUTHOR), Nishimura, Takashi13 (AUTHOR)
Source: Hepatology Research. May2025, Vol. 55 Issue 5, p741-751. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:13866346
DOI:10.1111/hepr.14171